Active immunotherapy of stage IV renal cell cancer using autologous tumor cells

Schärfe, T.; Becht, E.; Klippel, K. F.; Jacobi, G. H.; Hohenfellner, R.

doi:10.1007/bf00632186

Cited by 17 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An increase in the level of IgG antibodies to autologous tumor cells was associated with stable disease or tumor remission. Loss of antibody activity coincided with or preceded a decline in clinical status [19], The incidence and magnitude of the response in our series were substantially less than those reported by Tykkä et al [45] and Tallberg et al [44], We like others could not repeat their good results [4,15,27,33,40], However, in this study, as in those reported by other authors, only the immunological part of the study by Tallberg et al [44] was repeated and no effort was dedicated to the use of trace elements and amino acids given as supportive measures to the patient treated by specific, active immunotherapy. Rationales for the use of trace elements and amino acids (glycine and glutamine) were based on the blocking effect on induced leukemia in rats.…”

Section: Discussioncontrasting

confidence: 49%

“…Since the first report of tumorspecific immunotherapy with polymerized autologous primary and metastatic tumor vaccine by Tykkä et al [45], this approach has been used by several centers in the USA and in Europe [4,15,27,33,40], In the follow ing, we describe our own experience with this form of immunotherapy. The number of patients with métastasés in multiple organ sites is shown in parentheses.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Autologous Anticancer Antigen Preparation for Specific Immunotherapy in Advanced Renal Cell Carcinoma

Kurth¹,

Marquet²,

Zwartendijk³

et al. 1987

Eur Urol

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 49%

Section: Introductionmentioning

confidence: 99%

Autologous Anticancer Antigen Preparation for Specific Immunotherapy in Advanced Renal Cell Carcinoma

Kurth¹,

Marquet²,

Zwartendijk³

et al. 1987

Eur Urol

View full text Add to dashboard Cite

“…Ljungberg et al [8] stated, based on flow cytometric analysis of metastasized renal cell carcinomas, that patients with "diploid or peridiploid" tumors, in contrast to patients with aneuploid tumors, benefited from aggressive surgical therapy including resection of metastases. A minority of tumors respond impressively to immunologic therapeutic modalities [19]. It remains to be seen whether DNA cytometry by means of automated image analysis will provide criteria that enable the response to such treatment modalities to be predicted and, therefore, allow more individual therapeutic planning.…”

Section: Discussionmentioning

confidence: 99%

“…After three more years the CT scan revealed two small lesions of an uncertain grade of malignancy and lung metastases. Complete remission of the lung metastases as well as stable disease of the kidney lesions was achieved by the use of a specific vaccination therapy using autologous tumor ceils [19]. All other patients are alive without evidence of disease.…”

Section: Correlation Of Dna Histogram With Clinical Course Of Patientsmentioning

confidence: 98%

See 1 more Smart Citation

Parenchyma-sparing surgery for renal tumors

Stöckle¹,

Thüroff²,

Störkel³

et al. 1991

World J Urol

Self Cite

View full text Add to dashboard Cite

Between 1969Between und 1989 conservative surgery for kidney tumors was performed in 123 patients. In 49 patients there was an imperative indication for a parenchyma-sparing operation because nephrectomy would have made dialysis obligatory. Thirty-five of these 49 patients show no signs of tumor progression after a mean follow-up of 4.5 years. Known metastases were present in 3 of 6 patients who died as a result of their tumors. In two patients there was a recurrence after 1 and 5 years, respectively, requiring a second organ-preserving operation. In one further patient we suspect that multiple small tumor lesions may be present 2 years after the first operation. In 74 patients with a healthy contralateral kidney the tumor was enucleated by choice (elective indication). Sixty-eight of these 74 patients show no signs of tumor progression after a mean follow-up period of 3.3 years. One patient died from tumor metastases. Two patients had tumor recurrence, requiring nephrectomy and enucleation, respectively. Fifty-seven enucleated tumors were available for image analysis DNA cytometry. Only the two patients with a hypertriploid tumor died from their cancer.Until now radical nephrectomy has been regarded as standard therapy for non-metastasized renal cell carcinoma [15,18,21]. This operation has been accepted because of its theorized advantage of more complete resection. A parenchyma-sparing operation has only been performed on patients in whom radical nephrectomy would result in renal failure requiring hemodialysis (imperative indication), such as those with a single kidney, bilateral tumors, dysfunctional contralateral kidney or chronic renal failure. However, the widely used partial nephrectomy in these instances may result, in certain cases, in insufficient residual renal parenchyma [14]. Simple enucleation of the tumor, together with a small surrounding margin of normal renal tissue, is an alternative technique to this * To whom correspondence should be addressed approach. The surprisingly good prognosis of patients, which were treated by enucleation in the imperative group [1], encouraged us over the past 9 years to perform parenchyma-sparing operations also on patients with small peripheral tumors and normal contralateral kidneys (elective indication). In addition, these small and mostly asymptomatic kidney tumors, which only a few years ago were rarely diagnosed, are being detected more frequently by ultrasound. Thus, the incidence of asymptomatic renal tumors increased from 10% in 1978 to 70°70 in 1989, while the classic symptoms of flank pain, hematuria and palpable mass were found in less than 10% of the cases, Here we present the operative technique, complications, patient outcome and preliminary results of image analysis DNA cytometry. Between 1969 and, conservative surgery of kidney tumors was performed in 123 patients. Conservative surgery was imperative for 49 of the patients (18 female, 31 male) aged 38 to 77 years (average age 59 years). A total of 23 patients had metachronous or synchronous bila...

show abstract

Characterization of conservatively resected renal tumors using automated image analysis DNA cytometry

Stöckle¹,

Störkel²,

Mielke³

et al. 1991

Cancer

Self Cite

View full text Add to dashboard Cite

The DNA histograms of 57 conservatively resected renal tumors were studied using automated image analysis DNA cytometry (Leytas II). Forty‐nine of the analyzed tumors were renal cell carcinomas, six were oncocytomas, one was an angiomyolipoma, and one was a renal cell adenoma. On the basis of their DNA histograms, diploid, tetraploid, and aneuploid tumors could be distinguished. Aneuploid tumors could be subtyped further according to the DNA content of the stem cell line as hyperdiploid, hypertriploid, or hypertetraploid. Eight of the tumors were characterized by a combination of diploid and hypertriploid stem cell lines. During a mean follow‐up of 5 years, only the two patients with a pure hypertriploid tumor died of distant metastases. These results indicate that automated DNA image analysis cytometry is able to differentiate among several types of renal tumors with obviously different prognoses.

show abstract

Active immunotherapy of stage IV renal cell cancer using autologous tumor cells

Cited by 17 publications

References 25 publications

Autologous Anticancer Antigen Preparation for Specific Immunotherapy in Advanced Renal Cell Carcinoma

Autologous Anticancer Antigen Preparation for Specific Immunotherapy in Advanced Renal Cell Carcinoma

Parenchyma-sparing surgery for renal tumors

Characterization of conservatively resected renal tumors using automated image analysis DNA cytometry

Contact Info

Product

Resources

About